NEKTAR THERAPEUTICS
252 institutions still hold NEKTAR THERAPEUTICS as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
Nektar Therapeutics (NKTR, CUSIP 640268306) entered Q1 2026 with $1.7B of institutional 13F value across 200 institutional accounts — a holder profile appropriate for a clinical-stage biopharmaceutical company whose proprietary polymer-conjugation and drug-delivery platform underpins a pipeline spanning oncology, immunology, and pain, with its lead assets reaching late-stage clinical development that generates institutional conviction at the fundamental biotech manager tier. The defining Q1 signal: FMR LLC added $305M — a massive conviction build at a size representing approximately 18% of the total reported institutional value in a single quarter — alongside 6 new positions among an already-concentrated 200-holder universe. For smart-money trackers, NKTR's Q1 filing is one of the highest-conviction-position events in this batch, with FMR's $305M add signaling fundamental confidence in the company's pipeline readouts and potential partnership or acquisition opportunities at the large-cap-biotech valuation tier. The stock's institutional footprint reflects both generalist healthcare-fundamental managers and specialized biotech-conviction players.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.